UPDATE: Piper Jaffray Cuts PT to $27 on Impax Laboratories on Rytary Launch Visibility | BioSpace - Financial Content

BioSpace.com

Biotech and Pharmaceutical
News & Jobs

NEWSLETTERS
FREENewsletters
Archive

NEWS
News bySubject
News byDisease
News byDate
PLoS
SearchNews

CAREER NETWORK
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

DIVERSITY

HOTBEDS
Regional News
BiotechBay™
BiotechBeach™
Genetown™
PharmCountry™
BioCapital™
BioMidwest™
BioNC™
BioForest™
SouthernPharm™
BioCanadaEast™
US Device™

INVESTOR
Market Summary
News
IPOs

PROFILES
CompanyProfiles

START UPS
Companies
Events

INTELLIGENCE
BioPharm Insight

INDUSTRY EVENTS
Biotech Events
Post an Event

RESOURCES
RealEstate
Business Opportunities


Markets Stocks Mutual Funds & ETF's Sectors Tools Overview Market News Market Videos Currencies International Treasury & Bonds Search InvestCenter Recent Quotes View Full List My Watchlist Create Watchlist Indicators Dow Jones Industrial Average NASDAQ Composite Standard & Poors 500 NYSE COMPOSITE INDX Gold Crude Oil UPDATE: Piper Jaffray Cuts PT to $27 on Impax Laboratories on Rytary Launch Visibility By: Latest Articles from Benzinga.com Posted on February 26, 2013 at 10:38 AM EST Piper Jaffray maintained Impax Laboratories (NASDAQ: IPXL ) with an Overweight rating and lowered the price target from $29.00 to $27.00. Piper Jaffray commented, "With a compelling net cash position of now close to $460M... in the context of a $1.3B market cap and 2013 operating cash flows pushing the Read More >> Related Stocks: IMPAX LABORATORIES, Inc. Stock Market XML and JSON Data API provided by FinancialContent Services, Inc. Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes. Markets are closed on certain holidays. Stock Market Holiday List By accessing this page, you agree to the following Privacy Policy and Terms and Conditions. Press Release Service provided by PRConnect. Stock quotes supplied by Telekurs USA Postage Rates Bots go here